Compare · DXCM vs NURO
DXCM vs NURO
Side-by-side comparison of DexCom Inc. (DXCM) and NeuroMetrix Inc. (NURO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NURO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 1016.2x NURO ($29.1M).
- DXCM has hit the wire 4 times in the past 4 weeks while NURO has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for NURO).
- Company
- DexCom Inc.
- NeuroMetrix Inc.
- Price
- $76.60-0.07%
- $4.57+5.42%
- Market cap
- $29.58B
- $29.1M
- 1M return
- +7.54%
- -
- 1Y return
- -8.85%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2004
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
NeuroMetrix Inc.
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest NURO
- SEC Form 15-12G filed by NeuroMetrix Inc.
- SEC Form EFFECT filed by NeuroMetrix Inc.
- SEC Form EFFECT filed by NeuroMetrix Inc.
- SEC Form EFFECT filed by NeuroMetrix Inc.
- SEC Form EFFECT filed by NeuroMetrix Inc.
- SEC Form EFFECT filed by NeuroMetrix Inc.
- SEC Form EFFECT filed by NeuroMetrix Inc.
- SEC Form EFFECT filed by NeuroMetrix Inc.
- SEC Form EFFECT filed by NeuroMetrix Inc.
- SEC Form EFFECT filed by NeuroMetrix Inc.